title: Melanoma: smart therapeutic strategies in immuno-oncology.
authors.affiliation: Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France.
authors.forename: Alexander M M
authors.initials: AM
authors.lastname: Eggermont
authors.affiliation: Department of Dermatology, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Robert
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D000074324:Ipilimumab; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D016176:T-Lymphocyte Subsets / Q000276:immunology; D035703:Therapies, Investigational
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D047428:Protein Kinase Inhibitors; D000077594:Nivolumab; C582435:pembrolizumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048369:MAP Kinase Kinase 1